📱 Check out our Patient Portal - Track your health and symptoms in one place. Manage your care with our easy-to-use health tracking system.
We use cookies to enhance your experience and analyze site usage. By clicking "Accept All", you consent to our use of cookies. You can customize your preferences or learn more about our privacy practices.
A comprehensive comparison of hypoparathyroidism treatments available in some countries. This information is for educational purposes and should not replace medical advice from your healthcare provider.
| Treatment | Type | Route | Status | Advantages | Considerations |
|---|---|---|---|---|---|
| Standard of Care (Calcium + Active Vitamin D) | Calcium and active vitamin D replacement | Oral (frequent daily dosing) | Approved in many countries, including US, EMA, UK, Canada, Japan, Australia, China |
|
|
| Teriparatide (Forteo) | Short-acting PTH analog | 1-4 daily injections or continuous pump delivery | Used off-label for HP in many countries |
|
|
| Palopegteriparatide (Yorvipath) | Long-acting PTH analog | Once daily injection | Approved in EU, US. Approved without reimbursement in: UK, Canada, Australia. Approved for hypoparathyroidism |
|
|
| Treatment | Sponsor | Type | Mechanism | Route | Phase | Comments |
|---|---|---|---|---|---|---|
| Encaleret | BridgeBio | PTH1R agonist | Oral, small molecule PTH1R agonist | Oral | ADH1: Ph3 complete | HP: Ph3 planned | Ph3 primary endpoint (in ADH1) met. Positive Ph2 proof of concept data in post-surgical HP |
| Eneboparatide | AstraZeneca | PTH1R agonist | Long-acting PTH1R agonist | Daily injection | Ph 3 in progress | Designed to provide more physiologic Ca control. Once-daily dosing. Ph3 primary endpoint met |
| Canvuparatide | MBX Biosciences | PTH replacement | Long-acting, peptide PTH analog | Weekly injection | Ph3 planned | Weekly dosing. May appeal to patients seeking fewer injections |
| EB612 | Entera Bio | PTH replacement | Oral PTH(1-34) | Oral | Ph2 planned | First oral PTH replacement candidate. Multiple daily dosing likely required. Very early in development |
| XH02 | PUMCH | Endogenous PTH support | mRNA-based PTH production | Injection | Pre-clinical development | Novel, mRNA-based approach. Potential for sustained, endogenous PTH production. Very early stage |
| Gubra PTH | Camrus & Gubra | PTH replacement | Long-acting PTH analog | Injection | Pre-clinical development | Long-acting PTH analog using depot technology. Goal is less frequent dosing |
Note: Septerna (SEP786) was removed from this list as they have paused their program after Phase 1 safety findings. XH02 (PUMCH) and Gubra PTH are included as they represent novel approaches in early development, though they are still far from clinical data.
This information is for educational purposes only and should not replace professional medical advice. Treatment decisions should be made in consultation with your healthcare provider who understands your individual medical situation, needs, and preferences.
Availability, approval status, and reimbursement of these treatments vary significantly by country and region. Always consult with your doctor or specialist about what options are available to you.